A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2018
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Antiphospholipid syndrome
- Focus Adverse reactions
- Acronyms TRAPS
- 12 Jul 2018 Results published in the Blood.
- 27 Jan 2018 Status changed from recruiting to discontinued.
- 02 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.